
Section 3.2.P.2 is where an applicant explains why the medicine is formulated, manufactured and packaged the way it is. Written well, it turns a set[…]

Module 1 is the only part of the CTD that is not harmonised internationally, and it is where many otherwise strong dossiers stumble. For EU[…]

Every marketing authorisation application in the EU is built on the same skeleton: the Common Technical Document (CTD). Understanding how its five modules relate to[…]

Pricing and reimbursement remain national decisions in the EU, but they are no longer taken in isolation. Since the mid-2010s, groups of Member States have[…]

Every marketing authorisation holder is legally required to keep its product information up to date with current scientific knowledge. In practice, that obligation depends on[…]

Radiopharmaceuticals are moving from diagnostic imaging into targeted therapy. Radioligand therapies and theranostic pairs, where one molecule is used both to image and to treat,[…]

For the first time in twenty years, the European Commission has revised Annex 19 of the EU GMP Guide on reference and retention samples. The[…]

Every complaint about a medicine, whether a cracked vial, an unusual smell or a missing leaflet, can be the first sign of a wider quality[…]

Pharmacovigilance obligations continue through a cyber attack, an IT outage, a vendor failure or the unexpected absence of the QPPV. Expedited reporting timelines still run,[…]

Medication errors are among the most preventable sources of harm in the use of medicines, and EU pharmacovigilance law brings them explicitly into scope. For[…]